Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 912 participants.
Also called NCT01029886
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 912 participants
- Sponsor
- Registry
-
NCT01029886
-
- Other papers using this trial's data
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Argentina, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, India, Israel, Italy, Mexico, Poland, Romania, Slovakia, South Africa, South Korea, Spain, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT01029886. Randomized; no masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2011-01 (actual). Results posted on 2012-03-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- exenatide once weekly
- Intervention (Drug)
- liraglutide
- Lead sponsor
- AstraZeneca
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01029886- Content hash
11123d64bbb49df0f652fc6a9a1ec2d1d1a1147b8dc5019a3d9b30c56f03bd45